ArticleTherapeutic advances in hematology2013
Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions.
Article in Therapeutic advances in hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hematopoietic stem cell transplantation for people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility.Bone marrow transplantation · 2018Pooled it
- Article
- Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania.BMJ global health · 2025Article
- Hematopoietic Stem Cell Transplantation in Sickle Cell Disease.Advances in experimental medicine and biology · 2025Review
- Article
- Gene-environmental influence of space and microgravity on red blood cells with sickle cell disease.NPJ genomic medicine · 2024Review
- Mesenchymal Stem Cell-Induced Neuroprotection in Pediatric Neurological Diseases: Recent Update of Underlying Mechanisms and Clinical Utility.Applied biochemistry and biotechnology · 2024Review
- Diverse Approaches to Gene Therapy of Sickle Cell Disease.Annual review of medicine · 2023Review
- Role of abatacept in the prevention of graft-Therapeutic advances in hematology · 2023Review
- ADaPTS "(AD)olescents (P)ath through (T)ransplant (S)ickle cell disease".Health and quality of life outcomes · 2022Article
- Effect of expansion of human umbilical cord blood CD34 + cells on neurotrophic and angiogenic factor expression and function.Cell and tissue research · 2022Article
- Sideroblastic anaemia in a patient with sickle cell disease.BMJ case reports · 2022Article
- Treatment decision-making in sickle cell disease patients.Journal of community genetics · 2022Article
- The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.PharmacoEconomics · 2021Review
- Neglected No More: Emerging Cellular Therapies in Traumatic Injury.Stem cell reviews and reports · 2021Review
- How Ancestry Influences the Chances of Finding Unrelated Donors: An Investigation in Admixed Brazilians.Frontiers in immunology · 2020Article
- Blood rheology biomarkers in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Recent Advances in the Treatment of Sickle Cell Disease.Frontiers in physiology · 2020Review
- Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
With rapidly expanding evidence of benefit reported by several groups, allogeneic hematopoietic stem-cell transplantation has become an acceptable treatment option for sickle cell disease. It is currently the only curative therapy available. Hematopoietic stem-cell transplantation was offered primarily as a therapeutic option for severe sickle cell disease in the context of myeloablative matched sibling donor transplants over the last two decades and helped to establish the benefits of transplantation for this disorder. While this approach provided proof of principle, the disadvantages and limitations of transplantation became evident along the way. It has been recognized that transplantation for sickle cell disease does not need to adhere strictly to the principles of transplantation for malignant disorders, such as achievement of full donor cell chimerism. As reviewed here, in recent years the transplant community has set out to explore ways to make stem-cell transplantation more available to patients with the disease, define indications and better timing, and offset toxicities with novel approaches to conditioning and better supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.